drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific monoclonal antibody)
drug_description
Intravenous anti‑CD20×anti‑CD3 bispecific antibody (T‑cell–redirecting IgG) that links CD3 on T cells to CD20 on B cells, activating cytotoxic T cells and inducing lysis of CD20+ malignant B cells.
nci_thesaurus_concept_id
C119615
nci_thesaurus_preferred_term
Odronextamab
nci_thesaurus_definition
A bispecific, human monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 monoclonal antibody REGN1979 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, odronextamab binds to both T-cells and CD20-expressing tumor B-cells, which cross-links the T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific monoclonal antibody that binds CD3 on T cells and CD20 on B cells, physically linking them to activate and redirect cytotoxic T cells to lyse CD20-positive malignant B cells via immune synapse formation, degranulation, and cytokine release.
drug_name
Odronextamab
nct_id_drug_ref
NCT06149286